Uro Flash Vol-11, No-1, 2026

Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate and a major cause of lower urinary tract symptoms (LUTS) in aging men. The prevalence of BPH increases with age, with histological evidence found in 50–60% of men in their 60s and up to 80–90% in those over 70 years.

Vitamin D and its analogs have emerged as potential therapeutic agents for LUTS, owing to their ability to inhibit growth factor signalling and reduce inflammation. Evidence suggests that increasing vitamin D intake through diet or supplements reduces prostate volume and the prevalence of BPH.

Nitrofurantoin (NF) is a synthetic antimicrobial agent derived from furan, containing a nitro group and a hydantoin side chain. It was first identified and approved by the U.S. Food and Drug Administration (FDA) in 1953 for the treatment of uncomplicated lower urinary tract infections (UTIs). Several major clinical guidelines, including those from the Infectious Diseases Society of America (IDSA), now recommend nitrofurantoin as a first-line agent for uncomplicated lower UTIs.